Systemic Lupus Erythematosus

You have full text access to this OnlineOpen article

Combined oral contraceptive use and the risk of systemic lupus erythematosus

  1. Marie-odile Bernier1,*,
  2. Yann Mikaeloff2,4,
  3. Marie Hudson3,
  4. Samy SuissA3,†

Article first published online: 30 MAR 2009

DOI: 10.1002/art.24398

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 61, Issue 4, pages 476–481, 15 April 2009

Additional Information

How to Cite

Bernier, M.-o., Mikaeloff, Y., Hudson, M. and SuissA, S. (2009), Combined oral contraceptive use and the risk of systemic lupus erythematosus. Arthritis & Rheumatism, 61: 476–481. doi: 10.1002/art.24398

Author Information

  1. 1

    McGill Pharmacoepidemiology Research Unit, McGill University, Montreal, Quebec, Canada

  2. 2

    McGill Pharmacoepidemiology Research Unit, McGill University, Montreal, Quebec, Canada

  3. 3

    McGill Pharmacoepidemiology Research Unit, McGill University, and SMBD Jewish General Hospital, Montreal, Quebec, Canada

  4. 4

    INSERM U822 and Assistance Publique Hôpitaux de Paris, Bicêtre University Hospital, Le Kremlin Bicêtre, France

  1. †

    Dr. Suissa has received consultancies and funding for other projects from Organon and Schering.

*Centre for Clinical Epidemiology, SMBD Jewish General Hospital, 3755 Cote Ste Catherine Road, Montreal, Québec, Canada H3T 1E2

Publication History

  1. Issue published online: 30 MAR 2009
  2. Article first published online: 30 MAR 2009
  3. Manuscript Accepted: 5 JAN 2009
  4. Manuscript Received: 24 JUL 2008

Funded by

  • Canadian Institutes of Health Research
  • Canadian Foundation for Innovation
  • Distinguished Investigator Award from the Canadian Institutes of Health Research

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (81K)

REFERENCES

  • 1
    Cooper GS, Dooley MA, Treadwell EL, St. Clair EW, Parks CG, Gilkeson GS. Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus [review]. Arthritis Rheum 1998; 41: 1714–24.
    Direct Link:
  • 2
    Grimaldi CM, Hill L, Xu X, Peeva E, Diamond B. Hormonal modulation of B cell development and repertoire selection. Mol Immunol 2005; 42: 811–20.
  • 3
    Skouby SO. Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur J Contracept Reprod Health Care 2004; 9: 57–68.
  • 4
    Taylor T, Keyse L, Bryant A. Contraception and sexual health 2005/06: a report on research using the ONS Omnibus Survey produced by the Office for National Statistics on behalf of the Department of Health. London: Office for National Statistics; 2006.
  • 5
    Petri M, Robinson C. Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum 1997; 40: 797–803.
    Direct Link:
  • 6
    Grimes DA, LeBolt SA, Grimes KR, Wingo PA. Systemic lupus erythematosus and reproductive function: a case-control study. Am J Obstet Gynecol 1985; 153: 179–86.
  • 7
    Strom BL, Reidenberg MM, West S, Snyder ES, Freundlich B, Stolley PD. Shingles, allergies, family medical history, oral contraceptives, and other potential risk factors for systemic lupus erythematosus. Am J Epidemiol 1994; 140: 632–42.
  • 8
    Cooper GS, Dooley MA, Treadwell EL, St. Clair EW, Gilkeson GS. Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case–control study. Arthritis Rheum 2002; 46: 1830–9.
    Direct Link:
  • 9
    Bengtsson AA, Rylander L, Hagmar L, Nived O, Sturfelt G. Risk factors for developing systemic lupus erythematosus: a case-control study in southern Sweden. Rheumatology (Oxford) 2002; 41: 563–71.
  • 10
    Sanchez-Guerrero J, Karlson EW, Liang MH, Hunter DJ, Speizer FE, Colditz GA. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum 1997; 40: 804–8.
    Direct Link:
  • 11
    Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum 2007; 56: 1251–62.
    Direct Link:
  • 12
    Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997; 350: 1097–9.
  • 13
    Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45: 419–25.
    Direct Link:
  • 14
    Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 302: 766–8.
  • 15
    Lawrenson R, Williams T, Farmer R. Clinical information for research; the use of general practice databases. J Public Health Med 1999; 21: 299–304.
  • 16
    Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, et al. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686–9.
  • 17
    Nightingale AL, Farmer RD, de Vries CS. Incidence of clinically diagnosed systemic lupus erythematosus 1992–1998 using the UK General Practice Research Database. Pharmacoepidemiol Drug Saf 2006; 15: 656–61.
    Direct Link:
  • 18
    Somers EC, Thomas SL, Smeeth L, Schoonen WM, Hall AJ. Incidence of systemic lupus erythematosus in the United Kingdom, 1990–1999. Arthritis Rheum 2007; 57: 612–8.
    Direct Link:
  • 19
    Kassi E, Vlachoyiannopoulos PG, Kominakis A, Kiaris H, Moutsopoulos HM, Moutsatsou P. Estrogen receptor α gene polymorphism and systemic lupus erythematosus: a possible risk? Lupus 2005; 14: 391–8.
  • 20
    Lee YJ, Shin KS, Kang SW, Lee CK, Yoo B, Cha HS, et al. Association of the oestrogen receptor α gene polymorphisms with disease onset in systemic lupus erythematosus. Ann Rheum Dis 2004; 63: 1244–9.
  • 21
    McMurray RW, May W. Sex hormones and systemic lupus erythematosus: review and meta-analysis. Arthritis Rheum 2003; 48: 2100–10.
    Direct Link:
  • 22
    Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest 2002; 109: 1625–33.
  • 23
    Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550–8.
  • 24
    Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, Mestanza-Peralta M, Lara-Reyes P, Seuc AH, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2539–49.
  • 25
    Lockshin MD, Buyon JP. Estrogens and lupus: bubbling cauldron or another overrated witches' brew? [editorial]. Arthritis Rheum 2007; 56: 1048–50.
    Direct Link:
  • 26
    Sammaritano LR. Therapy insight: guidelines for selection of contraception in women with rheumatic diseases. Nat Clin Pract Rheumatol 2007; 3: 273–81.
  • 27
    Grimaldi CM, Jeganathan V, Diamond B. Hormonal regulation of B cell development: 17 β-estradiol impairs negative selection of high-affinity DNA-reactive B cells at more than one developmental checkpoint. J Immunol 2006; 176: 2703–10.
  • 28
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–7.
    Direct Link:
  • 29
    Hopkinson ND, Doherty M, Powell RJ. The prevalence and incidence of systemic lupus erythematosus in Nottingham, UK, 1989–1990. Br J Rheumatol 1993; 32: 110–5.
  • 30
    Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England: relationship to ethnicity and country of birth. Arthritis Rheum 1995; 38: 551–8.
    Direct Link:
  • 31
    Barr SG, Zonana-Nacach A, Magder LS, Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2682–8.
    Direct Link:
  • 32
    Nagata C, Fujita S, Iwata H, Kurosawa Y, Kobayashi K, Kobayashi M, et al. Systemic lupus erythematosus: a case–control epidemiologic study in Japan. Int J Dermatol 1995; 34: 333–7.
    Direct Link:
  • 33
    Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399–406.
  • 34
    Rhew EY, Ramsey-Goldman R. Premature atherosclerotic disease in systemic lupus erythematosus: role of inflammatory mechanisms. Autoimmun Rev 2006; 5: 101–5.
  • 35
    Meesters EW, Hansen H, Spronk HM, Hamulyak K, Rosing J, Rowshani AT, et al. The inflammation and coagulation cross-talk in patients with systemic lupus erythematosus. Blood Coagul Fibrinolysis 2007; 18: 21–8.
  • 36
    Urowitz MB, Gladman D, Ibanez D, Fortin P, Sanchez-Guerrero J, Bae S, et al. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus 2007; 16: 731–5.
  • 37
    Mader R, Mishail S, Adawi M, Lavi I, Luboshitzky R. Thyroid dysfunction in patients with systemic lupus erythematosus (SLE): relation to disease activity. Clin Rheumatol 2007; 26: 1891–4.
  • 38
    Costenbader KH, Kim DJ, Peerzada J, Lockman S, Nobles-Knight D, Petri M, et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum 2004; 50: 849–57.
    Direct Link:
  • 39
    Formica MK, Palmer JR, Rosenberg L, McAlindon TE. Smoking, alcohol consumption, and risk of systemic lupus erythematosus in the Black Women's Health Study. J Rheumatol 2003; 30: 1222–6.
View Full Article (HTML) Get PDF (81K)